- Platform will include non-invasive, continuous measurement of
extensive range of biomarkers, custom cloud analytics, AI, and
first-of-its-kind biosensing wristband
- Bioptx engineering samples shipped to customers two years
earlier than previously scheduled to meet increasing demand
- Early introduction accelerates development of non-invasive
remote monitoring solutions for professional healthcare
Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”), a
global leader in photonics-based health monitoring and
communications solutions, today announced the Bioptx™ platform of
biomarker sensing products and solutions for the medical and
healthcare market. The Bioptx healthcare sensing platform is
expected to provide medical institutions, such as hospitals,
research clinics, pharmaceutical companies, medical device
manufacturers, and other healthcare providers, with the ability to
monitor the general wellness of individuals.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220208005453/en/
Sample Use of Rockley Bioptx Biosensing
Wristband (Photo: Business Wire)
The Bioptx sensing platform will integrate various sensing
capabilities, including Rockley’s patented silicon-photonics-based
laser technology. Rockley’s technology has the potential to
significantly enhance the range of biomarkers that can be detected
and measured by current sensors. The expanded range of biomarkers
will include core body temperature, blood pressure, body hydration,
alcohol, lactate, and glucose trends, among others. These new
measurement capabilities have the potential to transform healthcare
by providing real-time insights into a variety of health conditions
and by enabling early detection of multiple disease states.
The cloud analytics and AI capabilities of the Bioptx sensing
platform will allow medical institutions to analyze biomarker
information, monitor general health conditions, and track
population health metrics. These insights have the potential to
support and improve a variety of healthcare treatments, including
remote patient monitoring, medical therapies, management of chronic
conditions, and drug development.
The Bioptx sensing platform will include a range of hardware and
software solutions that enable non-invasive, continuous, and
real-time monitoring of multiple biomarkers, from a wearable
biosensing wristband to cloud analytics and artificial intelligence
(AI). Rockley also plans to offer additional cloud-based
subscription services that enhance the capabilities of the
biosensing platform.
The Bioptx line of sensing products, which will address specific
needs of the professional healthcare market, is the second product
line to leverage Rockley’s silicon-photonics-based biosensing
platform. The company’s VitalSpex™ product line will address the
consumer wearable market. Both product lines incorporate Rockley’s
highly disruptive silicon photonics technology and
clinic-on-the-wrist™ miniaturizing technology.
Rockley had previously projected that it would introduce
commercial products into the professional healthcare market in
2024. The announcement of the Bioptx product line and shipping of
engineering samples come two years earlier than projected to meet
the demand from our customers and partners. The company shipped the
first of its engineering samples to multiple customers in January
of 2022. The first commercial products in the Bioptx line are
expected to be available as early as the second half of 2022.
“Launching the Bioptx product line two years earlier than
planned represents a significant step forward in the deployment and
commercialization of our biomarker sensing platform and will allow
us to develop and refine our algorithms and analytics for the
healthcare market more quickly,” said Dr. Andrew Rickman, chairman
and chief executive officer of Rockley. “People are interested in
taking a more proactive role in managing their health, and
professional healthcare providers are looking for a holistic
approach to outcome-based programs. I believe our Bioptx biosensing
platform has the potential to significantly advance this new
approach by providing non-invasive, continuous remote patient
monitoring that’s much more accurate and tracks a broader range of
health conditions.”
“With the potential for additional revenue that could begin as
early as 2023, the new Bioptx platform also gives Rockley the
opportunity to offer new software and cloud services in addition to
the wristband,” added Mahesh Karanth, Rockley's chief financial
officer. “These new opportunities build on our already strong
customer base of two of the world’s top ten medical equipment and
device manufacturers and twelve leading global consumer electronics
companies, potentially increasing Rockley’s market opportunity by
as much as $15 billion.”
Rockley intends to use the data and learnings gathered from the
Bioptx line to further refine the sensing algorithms, cloud
analytics, and AI of its sensing platform. The launch of a
healthcare-specific biosensing product line is expected to
accelerate Rockley’s access to data and the refinement and
expansion of its platform functionality. Rockley expects that these
refinements will allow it to expand the intended uses of the Bioptx
product line and move forward with plans to seek certification from
the U.S. Food and Drug Administration (FDA) that products in the
Bioptx line meet the FDA’s definition of a medical device, per
Section 201(h) of the Food, Drug, and Cosmetic Act.
Rockley expects that customers will initially use its Bioptx
platform to monitor the general wellness of individuals under care
or in studies. After products in the Bioptx line receive approval
from the FDA or other regulatory agencies, Rockley anticipates that
customers will expand product use into preventive and diagnostic
care, such as remote patient monitoring and diagnosis.
More information about Rockley’s digital health monitoring
solution is available here:
https://rockleyphotonics.com/healthcare-sensing.
About Rockley Photonics
A global leader in photonics-based health monitoring and
communications solutions, Rockley Photonics is developing a
comprehensive range of photonic integrated circuits and associated
modules, sensors, and full-stack solutions. From next-generation
sensing platforms specifically designed for mobile health
monitoring and machine vision to high-speed, high-volume solutions
for data communications, Rockley is laying the foundation for a new
generation of applications across multiple industries. Rockley
believes that photonics will eventually become as pervasive as
micro-electronics, and it has developed a platform with the power
and flexibility needed to address both mass markets and a wide
variety of vertical applications.
Formed in 2013, Rockley is uniquely positioned to support
hyper-scale manufacturing and address a multitude of high-volume
markets. Rockley has partnered with numerous tier-1 customers
across a diverse range of industries to deliver the complex optical
systems required to bring transformational products to market.
To learn more about Rockley, visit rockleyphotonics.com.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release that are not historical facts
constitute “forward-looking statements” for purposes of the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include statements
regarding Rockley’s future expectations, beliefs, plans,
objectives, and assumptions regarding future events or performance.
The words “accelerate,” “advance,” “allow,” “anticipate,”
“believe,” “can,” “capability,” “continue,” “could,” “develop,”
“enable,” “estimate,” “eventual,” “expand, “expect,” “focus,”
“forward,” “future,” “goal,” “intend,” “may,” “might,”
“opportunity,” “outlook,” “plan,” “possible,” “position,”
“potential,” “predict,” “project,” “revolutionize,” “seem,”
“should,” “trend,” “vision,” “will,” “would” or other terms that
predict or indicate future events, trends, or expectations, and
similar expressions or the negative of such expressions may
identify forward-looking statements, but the absence of these words
or terms does not mean that a statement is not forward-looking.
Forward-looking statements in this press release include, but are
not limited to, statements regarding the following: (a) the
anticipated and potential features, scope, goals, and benefits of
the Company’s platform, products, and technology, including its
first-of-its-kind biosensing wristband, cloud analytics and AI; (b)
Rockley’s continued focus on the commercialization of its platform
in the health monitoring space and timing for the development
thereof; (c) Rockley’s strategy for monetizing the data collected
from its biomarking sensing products; (d) the potential for
continuous measurement of key biomarkers to transform healthcare by
providing real-time insights into a variety of health conditions
and enable early detection of multiple disease states; (e) the
potential to leverage data collected from Rockley’s biomarking
sensing products to improve a variety of healthcare treatments,
including remote patient monitoring, medical therapies, management
of chronic conditions, and drug development; (f) the timing for the
commercial availability of Rockley’s products; (g) the potential
effectiveness of the wearable sensing platform for determining key
biomarkers; (h) the expectation that the cloud-based analytics and
AI capabilities of Rockley’s platform can help develop a more
holistic assessment of a person’s health and well-being; (i)
Rockley’s belief that its cloud and AI infrastructure can enable
additional capabilities for the fast-growing digital health domain
and help individuals make more informed decisions about their
health and well-being; and (j) .
Forward-looking statements are subject to several risks and
uncertainties (many of which are beyond Rockley’s control) or other
assumptions that may cause actual results or performance to differ
materially from those expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, the following: (i) Rockley’s ability to achieve
customer acceptance and commercial production of its products and
technology, including in a timely and cost-effective manner; (ii)
Rockley’s ability to achieve customer design wins and convert
memoranda of understanding and development contracts into
production contracts; (iii) risks related to purchase orders,
including the lack of long-term purchase commitments, the
cancellation, reduction, delay, or other changes in customer
purchase orders, and if and to the extent customers seek to enter
into licensing arrangements in lieu of purchases; (iv) Rockley’s
history of losses and need for additional capital and its ability
to access additional financing to support its operations and
execute on its business plan, as well as the risks associated
therewith; (v) legal and regulatory risks; (vi) risks associated
with its fabless manufacturing model and dependency on third-party
suppliers; (vii) Rockley’s reliance on a few significant customers
for a majority of its revenue and its ability to expand and
diversify its customer base; (viii) Rockley’s financial
performance; (ix) the impacts of COVID-19 on Rockley, its customers
and suppliers, its target markets, and the global economy; (x)
Rockley’s ability to successfully manage growth and its operations
as a public company; (xi) fluctuations in Rockley’s stock price and
Rockley’s ability to maintain the listing of its ordinary shares on
the NYSE; (xii) Rockley’s ability to anticipate and respond to
industry trends and customer requirements; (xiii) changes in the
current and future markets in which Rockley is or may be engaged;
(xiv) risks related to competition and intellectual property; (xv)
market opportunity and demand for Rockley’s products and
technology, as well as the customer products into which Rockley’s
products and technology are incorporated; (xvi) risks related to
international operations; (xvii) risks related to cybersecurity,
privacy, and infrastructure; (xviii) risks related to financial and
accounting matters; (xix) general economic, financial, political,
and business conditions, both domestic and foreign; (xx) Rockley’s
ability to realize the anticipated benefits of its recently
completed business combination with SC Health Corporation; and
(xxi) Rockley’s ability to realize the anticipated benefits of
strategic partnerships, as well as other factors described under
the heading “Risk Factors” in Rockley’s quarterly report on Form
10-Q for the quarter ended September 30, 2021, and in other
documents Rockley files with the Securities and Exchange Commission
in the future.
The forward-looking statements contained in this press release
are based on various assumptions, whether or not identified in this
press release, and on Rockley’s current expectations, beliefs, and
assumptions and are not predictions of actual performance. If any
of these risks or uncertainties materialize, or should any of these
assumptions prove incorrect, actual results may differ materially
from those discussed in or implied by these forward-looking
statements. There can be no assurance that future developments
affecting Rockley will be those that have been anticipated. These
forward-looking statements speak only as of the date hereof and
Rockley does not intend to update or revise any forward-looking
statements, whether because of new information, future events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220208005453/en/
Media Debra Raine Rainemakers Telephone: +1 415-349-7432 Email:
rockley-pr@rainemakers.com
Investors Gwyn Lauber Rockley Photonics Telephone: +1
626-995-0001 Email: investors@rockleyphotonics.com
Rockley Photonics (NYSE:RKLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockley Photonics (NYSE:RKLY)
Historical Stock Chart
From Apr 2023 to Apr 2024
